NONOF — Novo Nordisk A/S

Novo Nordisk A/S (NONOF) is a drug manufacturers - general company listed on PINK. It is led by Lars Fruergaard Jorgensen, based in Novo Alle 1, Bagsvaerd, Denmark, 2880, with about 77,406 employees. Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Use this NONOF page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NONOF quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NONOF SEC filings page. Lician reads the product cache first so this HTML stays unique to Novo Nordisk A/S even when a live quote feed is slow.